Reference : Utilisation des antidiabetiques oraux en cas d'insuffisance renale.
Scientific journals : Article
Human health sciences : Urology & nephrology
Human health sciences : Pharmacy, pharmacology & toxicology
Human health sciences : Endocrinology, metabolism & nutrition
Utilisation des antidiabetiques oraux en cas d'insuffisance renale.
[en] Use of oral glucose-lowering agents in patients with renal impairment
SCHEEN, André mailto [Centre Hospitalier Universitaire de Liège - CHU > > Diabétologie,nutrition, maladies métaboliques >]
Revue Médicale Suisse
Yes (verified by ORBi)
[en] People with chronic kidney disease (CKD) of stages 3-4 (creatinine clearance <50 ml/min) represent 25-30% of type 2 diabetic patients, but the problem is often underrecognized or neglected in clinical practice. However, most of oral antidiabetic agents have limitations in case of renal impairment, either because they require a dose adjustment, or because they are contra-indicated for safety reasons. It is the case for metformin (risk of lactic acidosis) and for most sulfonylureas (risk of hypoglycaemia). New antidiabetic agents are better tolerated in case of CKD. However, the daily dose of dipeptidyl peptidase-4 inhibitors should be adjusted (except for linagliptin). Concerning new inhibitors of renal SGLT2 cotransporters, they have a reduced efficacy and their safety remains to be demonstrated in presence of CKD.
Researchers ; Professionals ; Students

File(s) associated to this reference

Fulltext file(s):

Open access
RMS utilisation des ADO insuff renal.pdfAuthor postprint358.63 kBView/Open

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.